Objective: To characterize progressive multifocal leukoencephalopathy (PML) lesions by contrastenhanced MRI and evaluate their metabolism using proton magnetic resonance spectroscopy ( 1 H-MRS) in the setting of immune reconstitution inflammatory syndrome (IRIS).
used a combination of conventional MRI and 1 H-MRS to characterize and measure the metabolism of brain lesions of patients with PML and PML-IRIS.
METHODS Standard protocol approvals, registration, and patient consents. This observational study has been registered at ClinicalTrials.gov (NCT01132053). Fortytwo patients gave written consent to participate in this study according to the institution's guidelines and were enrolled in an outpatient neurology clinic between 2005 and 2011.
Study subjects and design. PML diagnosis was established according to consensus criteria 8 : 10 (23.8%) patients had histology-confirmed PML, 24 (57.1%) patients had laboratoryconfirmed PML with positive JC virus (JCV) DNA PCR in CSF, 1 (2.4%) patient had both positive biopsy results and JCV detection in CSF, and 7 (16.7%) patients had possible PML based on clinical and radiologic findings. Patients with PML were divided into progressors or survivors, depending on survival shorter or longer than 1 year from onset of neurologic symptoms. 9 The presence of IRIS was determined on the basis of clinical and laboratory evaluation, including 1) evidence of immune reconstitution demonstrated by an increase of CD4ϩ T-cell counts and a decrease in HIV plasma RNA in HIVϩ patients or after discontinuation of immunosuppressive medication in HIVϪ patients, 2) sudden worsening of neurologic signs and symptoms occurring in the context of improved immunologic and virologic response, in contrast with the steady decline of PML progressors, and 3) absence of other pathogens or tumor. These criteria were further supported by the presence of swelling, mass effect, or CE on MRI in some cases. Patients were then classified as PML-simultaneous IRIS when IRIS occurred concomitantly with the initial manifestations of PML or PML-delayed IRIS when IRIS occurred in the setting of a known PML. 6 We performed imaging at the time of enrollment (baseline) and after 3, 6, and 12 months. Patients had a full neurologic examination by 2 neurologists (S.G. and I.J.K.). Karnofsky and modified Rankin Scale scores, CD4ϩ T-cell count, HIV plasma viral load (VL), if applicable, and medications were recorded.
Brain MRI and 1 H-MRS. Brain MRI was done using a 3-T scanner (General Electric, Waukesha, WI). Single voxel 1 H-MRS (2 ϫ 2 ϫ 2 cm 3 , 1.1 minute) of the PML lesions was obtained at the center of the PML lesion. Point-resolved spectroscopy spectra were acquired with a repetition time of 2 seconds, time to echo of 35 msec, spectral width of 5,000 Hz, and 2,048 time points with water-suppressed metabolite signal acquisitions as described previously. 7 We defined the combined lactate and lipid peaks at 1.3 ppm as lipid 1 (Lip1) and the combined lipid peak at 0.9 ppm and macromolecules peak at 0.87 ppm as lipid 2 (Lip2). T1-weighted imaging was performed with a magnetization prepared 3-dimensional sequence that provides excellent gray-white matter contrast. This sequence used multiple presaturation pulses followed by a delay and then an adiabatic inversion pulse at 500 msec before image acquisition. A 64-slice encode centric ordered spoiled gradient echo with 15°f lip angle was used for acquisition. A 24-cm field of view, 3-mm slice thickness, and 256 ϫ 256 matrix were used. Fluidattenuated inversion recovery was performed with the product sequence, 3-mm slices, 24-cm field of view, and 256 ϫ 256 matrix. In addition, patients received 0.1 ml/kg Magnevist. A post-contrast sequence was run 5 minutes after administration and as the last sequence of the examination. Image analysis. The presence of CE was determined by visual examination by 2 investigators (S.G. and I.J.K.). Spectral analysis was done using the LC model (Stephen Provencher Inc., Oakville, Canada) embedded in SAGE (GE Medical Systems). We measured the concentration of the following metabolites: N-acetylaspartate (NAA), choline (Cho), mI, and mobile lipids/ lactate (Lip1 and Lip2). Metabolites were expressed as ratios to creatine (Cr), a marker of basal metabolism.
Statistical analysis. Using Prism 4 for MacIntosh, we performed Mann-Whitney tests to compare age, CD4ϩ T-cell count, HIV plasma VL, Karnofsky and modified Rankin Scale scores, time until start of cART, and time until delayed IRIS between PML survivors (PML-S) and PML progressors (PML-P) and between patients with and without IRIS. Fisher exact test was used to compare HIV status, presence of IRIS, gender, and ethnicity between PML-P and PML-S. The Mann-Whitney test was applied on all comparisons of metabolite ratios between different groups. No adjustment for multiple comparisons was performed. A linear mixed-effects model with time as independent variable, thereby controlling for survival, and also controlling for enhancement was used to examine the longitudinal trends between patients with and without IRIS up to 1,000 days after symptom onset using SAS software. The correlation of within-subject measurements was modeled using the variancecovariance structure of compound symmetry, which yielded the equivalent model with random intercept and fixed time effect. The 2 variance components from the compound symmetry variance-covariance matrix of the within-subject metabolites were estimated using the restricted maximum likelihood estimation method. These variance-component estimates were then used iteratively in the estimation of the fixed effect (time effect). In addition, we used a logistic regression model to evaluate IRIS predictors, followed by a stepwise model selection procedure with entry significance level set at 0.05 and stay significance level set at 0.10 to obtain a parsimonious selection of the best predictors. This model yielded Lip1/Cr and CE as best predictors. We subsequently determined the threshold of the Lip1/Cr ratio based on sensitivity and specificity for IRIS and reassigned values as a binary outcome with a cutoff of 1.5. Threshold optimality was determined using the diagnostic measure of overall accuracy, which was defined as the sum of true positives and true negatives divided by the total number of measurements. The sensitivity and specificity that correspond to the maximum accuracy were selected as the optimal sensitivity and specificity.
RESULTS Study subject characteristics. Of 42 patients, 66.7% were survivors and 33.3% were progressors (table 1) . PML-P were older than PML-S ( p ϭ 0.004). There were no differences between the groups in gender or ethnicity. HIVϩ patients accounted for 57.1% of PML-S and 21.4% of PML-P ( p ϭ 0.05). HIVϩ PML-P had nonsignificant lower CD4ϩ T-cell counts at the time of the first MRI than HIVϩ PML-S ( p ϭ 0.19). HIV plasma RNA was comparable ( p ϭ 0.48). CD4ϩ T-cell counts in PML-P and PML-S HIVϪ groups were comparable ( p ϭ 0.54) (table 1). Underlying conditions for all HIVϪ patients are shown in table 1.
IRIS was more common in the PML-S group (57.1%) than in the PML-P group (7.1%) ( p ϭ 0.002) and was further subdivided into delayed IRIS or simultaneous IRIS (table 1) . Of PML-S-IRIS, 75% were HIVϩ and had a median CD4ϩ T-cell increase of 114/L (44 -567 L) and a median HIV VL decrease of 87,442 copies/mL (undetectable-228,083) by the time of IRIS onset. Only one patient with PML-IRIS received steroids at the time of the first MRI.
The Karnofsky and modified Rankin Scale scores were better in PML-S than in PML-P, who were first examined within 6 months of symptom onset ( p ϭ 0.02 and p ϭ 0.03, respectively) (table 1). There were no differences in Karnofsky and modified Rankin Scale scores between patients with and without IRIS at any of the 4 time points.
All HIVϩ patients were treated with cART. Immunosuppressive medications were decreased or stopped when possible. In addition, a total of 30 patients received mirtazapine, 10 8 patients were treated with mefloquine, 11 3 patients were treated with cytarabine, 12 and 2 were treated with interleukin-2 (table 1) .
A total of 101 MRIs were performed, of which only 11 were without injection of gadolinium and 2 were without concomitant 1 H-MRS, because of technical reasons.
Among PML-P, survival was limited to 70 -206 days (median 118.5 days) and, therefore, all patients except one, had only one MRI. Of 15 MRI scans obtained in the PML-P group, 1 occurred during an episode of IRIS. Among PML-S, 16 patients completed 4 MRI scans, 3 patients completed 3 MRI scans, 4 patients completed 2 MRI scans, and 5 patients completed 1 MRI scan. Of the 86 MRI scans in the PML-S group, 25 were obtained during episodes of IRIS.
Contrast enhancement. To determine whether CE was associated with a better outcome, we compared the incidence of CE on the first MRI of each patient performed within 6 months of symptom onset. There was no difference between the incidence of CE in PML-S and PML-P (11 of 16 [68.8%] vs 5 of 11 [45.5%], p ϭ 0.26).
Of the 25 MRI scans obtained during IRIS, 22 (88%) showed CE compared with only 10 of 65 (15.4%) MRI scans obtained in the absence of IRIS ( p Ͻ 0.0001).
H MR spectroscopy. Metabolite ratios in PML lesions do not differentiate PML-P and PML-S.
All first 1 H-MRS examinations of PML-P were obtained within 6 months of symptom onset and were thus compared with those of PML-S within the same time frame. No significant differences were found between the NAA/Cr, Cho/Cr, mI/Cr, Lip1/Cr, and Lip2/Cr ratios of 47 lesions of 16 PML-S and 36 lesions of 14 PML-P (data not shown). (16) No. patients with IRIS (HIV؉) 1 delayed (0) 8 delayed (5) 8 simultaneous (7) No. of days between PML and dIRIS, range (median) 93 (93) (n ϭ 1) 22-113 (61) (n ϭ 7)
No. of days between start of cART and dIRIS, range (median)
No. of days between start of cART and sIRIS, range (median)
Age, y, range (median) 36 The NAA/Cr ratio was lower in lesions of patients with IRIS (median 0.9 vs 0.99, p ϭ 0.02) ( figure  2A) . Conversely, the Cho/Cr ratio was markedly higher in lesions of patients with IRIS (median 0.45 vs 0.37, p ϭ 0.0001) ( figure 2B ). Furthermore, the mI/Cr ratio was elevated in the IRIS group (median 1.23 vs 1.09, p ϭ 0.02) ( figure 2C ). Finally, both the Lip1/Cr and Lip2/Cr ratios were markedly elevated during IRIS (median 1.73 vs 1.21 and 1.57 vs 0.96, p Ͻ 0.0001 and p ϭ 0.002) (figure 2, D and E).
There is a decrease in NAA and increase in Cho/Cr, mI/Cr, Lip1/Cr, and Lip2/Cr ratios in lesions of

CE is associated with elevated Cho/Cr ratios in PML-IRIS, whereas increases in lipid/Cr ratios are independent of
CE.
To determine whether CE was associated with a specific metabolic profile in patients with PML-IRIS, we compared metabolic ratios within PML lesions of patients with IRIS with and without CE within the voxel under consideration. We compared 35 enhancing lesions in 17 MRI scans of 9 patients with IRIS, with 48 nonenhancing lesions in 20 MRI scans of 11 patients with IRIS. Some patients had enhancing and nonenhancing lesions within the same MRI scan. The Cho/Cr ratio was significantly elevated in enhancing lesions (median 0.5 vs 0.39, p Ͻ 0.0001), whereas mI/Cr was decreased (median 1.16 vs 1.39, p ϭ 0.007). Lip1/Cr and Lip2/Cr ratios were not significantly different in lesions with or without CE (median 2.17 vs 1.69 and median 1.9 vs 1.94, p ϭ 0.07 and p ϭ 0.46, respectively). No difference was observed in NAA/Cr ratios (median 0.9 vs 0.82, p ϭ 0.39). These results suggest that elevation of lipid/Cr ratios as seen in IRIS was independent of CE, whereas the increase in the Cho/Cr ratio is associated with the presence of CE.
mI/Cr remains elevated in lesions of patients with PML-
IRIS over time.
Metabolite ratios were measured in 238 lesions of PML-S and 38 lesions of PML-P over the course of 8 to 4,526 days after symptom onset. Cho, Lip1, and Lip2 ratios decreased over time in the IRIS group, whereas NAA increased ( figure 3 ). Thirty months after symptom onset, there was no significant difference between any of the metabolite ratios in the IRIS and non-IRIS groups, except for the mI/Cr ratio, which remained higher in the IRIS group over time (mean difference 0.3418, p ϭ 0.01) ( figure 3 ).
Lip1/Cr ratio and CE in PML lesions are diagnostic indicators of IRIS.
We reclassified all PML lesions as having a Lip1/Cr ratio either greater than or less than 1.5 (see Statistical Analysis). Combining this mea- surement with the presence of CE allowed us to determine the probabilities of IRIS as shown in table 2. When a lesion had a Lip1/Cr ratio less than 1.5 and no CE, the likelihood of IRIS was only 13%. Conversely, a Lip1/Cr ratio greater than 1.5 and the presence of CE increased the likelihood of IRIS up to 79%.
DISCUSSION
Our study uncovered major differences in the metabolic profile of the brain lesions of patients with PML with IRIS compared with patients with PML without IRIS. These differences subsided over time, except for the mI/Cr ratio, which remained higher in PML-IRIS. We designed a diagnostic model for IRIS using the Lip1/Cr ratio and CE. These findings will be useful in the management of PML. Clinicians are often confronted with patients with PML whose condition worsens when taking cART or when immunosuppressive medications are discontinued, but classic MRI fails to differenti-ate IRIS from the natural progression of PML, especially in the absence of CE. In our study, some patients with IRIS already had a clinical worsening before CE was recognized on MRI or continued to improve after CE subsided. Therefore, CE by itself is not a reliable parameter to predict or follow IRIS, in line with previous observations. 13 Mobile lipids (Lip1 and Lip2) consist of triglyceride and cholesterol esters, which appear as a stress response. 14 The Lip1 peak also contains lactate. Both lipid peaks were elevated in IRIS compared with non-IRIS lesions. Higher lipid peaks were also observed in one HIVϩ and one HIVϪ patient with PML-IRIS. 15, 16 In addition, lipid peaks were identified in spectra obtained in multiple sclerosis (MS) plaques 17 and have been studied in brain tumors (reviewed in 14 ). Lipid/lactate peaks are highest in lesions with the most inflammation when 1 H-MRS results were correlated with stereotactic biopsy specimens of patients with MS 18 and normalize quickly over time. 19 These have also been observed in the acute phase of acute disseminated encephalomyelitis (ADEM). 20, 21 Increased lipid ratios in PML-IRIS are reminiscent of primary CNS lymphoma, 22 in which increased lipids were also visualized outside of the areas of CE. 23 PML-IRIS lesions are infiltrated by numerous CD8ϩ T cells. 4 On in vitro 1 H-MRS, the presence of lipids has been linked to the presence of immune cells, including T cells, 24 (reviewed in Delikatny et al. 14 ) , and, therefore, lipids have been proposed to be a marker for activated lymphocytes. 25 In addition, increased lipid concentrations may promote membrane fluidity, which will facilitate migration of T cells to the site of infection. 25 Therefore, the presence of increased lipid/Cr ratios in the setting of PML-IRIS may be caused by infiltration of activated T cells. Combining the Lip1/Cr ratio with CE allowed us to determine the probability of a patient to have IRIS and therefore is a useful clinical tool.
The NAA/Cr ratio was decreased in PML-IRIS lesions. NAA is a marker of neuronal integrity and is decreased in the context of neuronal or axonal damage. 18 NAA/Cr ratio reduction has been described in PML 26 and in clinically isolated syndrome, 27 ADEM, 28 and active MS lesions, 29 but also in normal-appearing white and gray matter of patients with MS. 30 Furthermore, whole-brain NAA is decreased in patients with benign MS 31 and is associated with cognitive decline in longitudinal studies. 32, 33 The NAA/Cr ratio returned to baseline over time in patients with PML-IRIS, suggesting that neuronal dysfunction was in part reversible after inflammation resolved.
Cho is a cell membrane component and is elevated in the setting of increased membrane turnover. An elevated Cho/Cr ratio has been found in other demyelinating and inflammatory processes such as MS, ADEM, and acute experimental allergic encephalomyelitis. 17,21,28,34 -36 Because elevated Cho was associated with CE, this biomarker by itself is not helpful to distinguish patients with IRIS from patients without IRIS. mI was higher in lesions of patients with PML-IRIS and is the only metabolite that remained elevated over time. mI is usually thought to be a marker of inflammation, but the mI/Cr ratio was lower in enhancing lesions from patients with IRIS. Similarly, the mI/Cr ratio decreases during the acute phase of ADEM 28 and then increases in the chronic phase. In addition, high mI is found in demyelinated and remyelinated MS lesions, suggesting that mI probably reflects accumulation of myelin breakdown products in the acute phase and astrocytosis later on. 18 A similar situation might occur in PML.
Our study has several limitations. A few patients with PML had negative JCV PCR in CSF, and PML was diagnosed using clinical and MRI criteria alone. 8 This is necessary because PML is a rare disease, and the sensitivity of the JCV CSF PCR has dropped to 58% in cART-treated patients with PML. 37 However, we are confident that these patients had the correct diagnosis, because all other infectious or tumoral pathologies were excluded, and the follow-up and immune responses to JCV were indistinguishable from those for patients with virologically or histologically proven cases. 5 We could not compare metabolites to the contralateral region, because these were also often affected by PML. Almost all our patients have an identified underlying disease, which itself might cause metabolite changes. Correlation between 1 H-MRS findings and histology could not be verified because no patients with PML-IRIS had a biopsy or autopsy at the time of ongoing IRIS. Although we were able to design a diagnostic model for the presence of IRIS, we did not have a second dataset to validate our findings. This is the largest 1 H-MRS study to date examining the features of PML-IRIS. Our observations are consistent with those made in other inflammatory and demyelinating diseases. Lipid/Cr ratios were ele- Probability of having IRIS based on contrast enhancement and Lip1/Cr ratio vated in patients with PML-IRIS regardless of the presence of CE, which suggest that these are a more consistent biomarker of PML-IRIS and might be explained by T-cell infiltrates in PML-IRIS lesions. Combining the Lip1/Cr ratio with CE allowed us to more accurately determine the probability of IRIS, which up to now constituted a challenge. 1 H-MRS may become a valuable tool to diagnose and track IRIS and might help guide its clinical management.
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